Racemisation: The Impurity That Weighs Exactly The Same

Almost every amino acid used in peptide synthesis has a chiral alpha carbon, and biological sequences are built from the L enantiomer. During a coupling step the alpha proton can be removed and replaced on the opposite face, which inverts that one centre. The product still has the same number of carbon, hydrogen, nitrogen, oxygen and sulfur atoms in the same connectivity. Only the spatial arrangement at one position has changed.

This matters for testing rather than for chemistry alone. Mass spectrometry separates ions by mass to charge ratio, and a diastereomer presents the same ratio as the target. A molecule of formula C45H69N11O12S has a monoisotopic mass of the same value whether one residue is L or D. No resolving power solves that, because there is no mass difference to resolve.

Reverse-phase chromatography is a better prospect, because diastereomers are not chemically equivalent and can differ in retention. Whether the two species actually separate depends on the sequence, the position of the inverted residue, the stationary phase and the gradient. In many cases the separation is partial or absent.

Where the inversion happens

Racemisation during solid-phase synthesis concentrates in the activation and coupling step, when the carboxyl group of the incoming residue is turned into a reactive species. An activated ester or an oxazolone intermediate makes the alpha proton considerably more acidic, and any base in the reaction mixture can remove it. Cysteine and histidine are the residues most often reported as vulnerable, with serine, aspartic acid and phenylglycine following.

A second route is hydrolytic. Held in aqueous solution at alkaline pH, a peptide bond region can epimerise slowly over weeks at ambient temperature, with the rate rising sharply with both pH and temperature. Aspartic acid residues are the usual site, because the succinimide intermediate that also drives deamidation opens with partial inversion at that centre.

• Coupling step: base-mediated proton abstraction from an activated residue, worst for cysteine and histidine.
• Cleavage and deprotection: strong acid conditions with long exposure times.
• Aqueous storage at alkaline pH: succinimide-mediated inversion at aspartic acid, on a timescale of weeks at ambient temperature.
• Acid hydrolysis during the test itself: 6 M hydrochloric acid at 110 degrees Celsius for 24 hours generates a small amount of D content that belongs to the method, not to the sample.

How chiral content is actually measured

The standard route runs through total hydrolysis followed by a chiral separation of the released amino acids. The peptide is hydrolysed in 6 M hydrochloric acid, typically at 110 degrees Celsius for 24 hours under nitrogen, then the free amino acids are derivatised with a chiral reagent so that the D and L forms become diastereomeric derivatives with different retention. Marfey's reagent, which is 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, is the common choice, read by reverse-phase liquid chromatography with ultraviolet detection at 340 nm.

Every one of these chiral methods destroys the sample. Hydrolysis reduces the peptide to its constituent amino acids, so the result describes residue-level D content across the whole molecule and cannot say which position inverted unless the sequence contains only one instance of that amino acid.

The failure mode: a diastereomer hidden under the main peak

The specific thing that goes wrong is co-elution. A single inverted residue in the middle of a twenty-residue sequence often changes retention by a few hundredths of a minute or not at all on a standard C18 column with a 0.1 percent trifluoroacetic acid and acetonitrile gradient. The diastereomer then sits inside the main peak, and integration at 214 nm counts it as product. A purity result reported as 98.7 percent by area at 214 nm can be arithmetically correct and still include diastereomeric material, because area percent describes what the detector separated, not what the molecule is.

It shows up, when it shows up at all, as peak asymmetry. A tailing factor drifting from near 1.0 towards 1.3 or 1.4 on a column that previously gave a symmetric peak, with no change in mass, is the signature worth following up with a chiral method.

What Aurum measures, and what it does not

Our published purity figures are reverse-phase HPLC area percent read at 214 nm. That number describes chromatographic separation of the material under a stated gradient. It is not a chiral measurement, and it does not resolve D amino acid content. Amino acid analysis after hydrolysis is not among the specifications Aurum publishes, Marfey derivatisation is not among the specifications Aurum publishes, and chiral purity specification for any item in the catalogue is not among the specifications Aurum publishes.

This belongs alongside the other limit we state plainly: HPLC purity is not net peptide content either, because counterions, residual water and residual solvent all sit outside the chromatographic peak.

Anyone who needs a chiral figure needs it measured directly by a laboratory that runs the method, on the lot in question, with the hydrolysis blank subtracted. Nothing in a standard purity certificate can be read as a substitute.

Common questions

Is a D amino acid the same as a different peptide?

It is a different molecule with the same formula. The two are diastereomers, not isomers of composition, so elemental analysis and mass measurement both return the same answer for each.

Why does acid hydrolysis create its own D content?

Prolonged exposure to 6 M hydrochloric acid at 110 degrees Celsius racemises a small fraction of the released residues. A method blank run on a known all-L standard establishes that background, commonly a few tenths of a percent, which is then subtracted from the sample result.

Can a chromatogram alone rule racemisation out?

No. Absence of a second peak is consistent with either absence of the diastereomer or failure to separate it. Only a chiral method distinguishes the two cases.

Which residues justify checking first?

Cysteine and histidine are the most frequently reported, followed by aspartic acid where a succinimide pathway is available. A sequence containing none of these has a lower prior probability, not a zero one.